Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis
Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
26746623
DOI
10.1016/j.eururo.2015.12.031
PII: S0302-2838(15)01240-3
Knihovny.cz E-zdroje
- Klíčová slova
- Complete response, Renal cell carcinoma, Survival, Targeted therapy,
- MeSH
- bevacizumab terapeutické užití MeSH
- cílená molekulární terapie MeSH
- fenylmočovinové sloučeniny terapeutické užití MeSH
- indazoly MeSH
- indoly terapeutické užití MeSH
- karcinom z renálních buněk farmakoterapie sekundární MeSH
- kritéria léčebné odpovědi MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfatické metastázy MeSH
- míra přežití MeSH
- nádory ledvin farmakoterapie patologie MeSH
- nádory plic farmakoterapie sekundární MeSH
- nenasazení léčby MeSH
- niacinamid analogy a deriváty terapeutické užití MeSH
- přežití bez známek nemoci MeSH
- protinádorové látky terapeutické užití MeSH
- pyrimidiny terapeutické užití MeSH
- pyrroly terapeutické užití MeSH
- receptory vaskulárního endoteliálního růstového faktoru antagonisté a inhibitory MeSH
- registrace MeSH
- senioři MeSH
- sorafenib MeSH
- sulfonamidy terapeutické užití MeSH
- sunitinib MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- bevacizumab MeSH
- fenylmočovinové sloučeniny MeSH
- indazoly MeSH
- indoly MeSH
- niacinamid MeSH
- pazopanib MeSH Prohlížeč
- protinádorové látky MeSH
- pyrimidiny MeSH
- pyrroly MeSH
- receptory vaskulárního endoteliálního růstového faktoru MeSH
- sorafenib MeSH
- sulfonamidy MeSH
- sunitinib MeSH
BACKGROUND: It is currently not known whether treatment with anti-vascular endothelial growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued in patients achieving a complete response (CR). OBJECTIVE: To assess outcomes for patients with mRCC achieving CR on targeted therapy (TT) and the survival of patients discontinuing TT after CR. DESIGN, SETTING, AND PARTICIPANTS: A national registry was used to identify patients achieving CR during first-line TT using bevacizumab, sunitinib, sorafenib, or pazopanib. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcomes were analysed using a log-rank test. RESULTS AND LIMITATIONS: A total of 100 patients achieving CR were identified out of 2803 patients. The median time to CR was 10.1 mo. Median progression-free survival (PFS) from TT initiation was 3.8 yr (95% confidence interval [CI] 2.9-4.6 yr) and the 5-yr overall survival (OS) was 80% (95% CI 70-91%). Patients discontinuing TT within 1 mo after achieving CR and those continuing TT beyond CR had similar OS (CI for difference in 2-yr post-CR OS -13% to 19%; p=0.3) and PFS (CI for difference in 2-yr post-CR PFS -29% to 17%; p=0.7). The limitations include the retrospective, registry-based data analysis. CONCLUSIONS: Achievement of CR on TT for mRCC was associated with excellent long-term prognosis. No significant differences in post-CR survival were observed between patients discontinuing TT after the date of CR and those who continued on TT, although the wide CIs cannot exclude important differences between the groups. PATIENT SUMMARY: According to this registry-based analysis, patients with metastatic renal cancer with no signs of disease (complete response) after treatment with targeted agents experience excellent long-term survival even if the treatment does not continue beyond the date of complete response.
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Oncology University Hospital Pilsen Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
